[go: up one dir, main page]

WO2007066017A3 - Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament - Google Patents

Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament Download PDF

Info

Publication number
WO2007066017A3
WO2007066017A3 PCT/FR2006/002693 FR2006002693W WO2007066017A3 WO 2007066017 A3 WO2007066017 A3 WO 2007066017A3 FR 2006002693 W FR2006002693 W FR 2006002693W WO 2007066017 A3 WO2007066017 A3 WO 2007066017A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
drug
concentrate
preparing
uhs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/002693
Other languages
English (en)
Other versions
WO2007066017A2 (fr
Inventor
Sami Chtourou Abdessatar
Claudine Mazurier
Michel Poulle
Bernadette Cauvin
Frederic Dhainault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to AU2006323849A priority Critical patent/AU2006323849B2/en
Priority to US12/095,949 priority patent/US20080318841A1/en
Priority to JP2008543870A priority patent/JP2009518368A/ja
Priority to EP06841898A priority patent/EP1962885A2/fr
Priority to CA002633102A priority patent/CA2633102A1/fr
Priority to BRPI0619728-0A priority patent/BRPI0619728A2/pt
Publication of WO2007066017A2 publication Critical patent/WO2007066017A2/fr
Publication of WO2007066017A3 publication Critical patent/WO2007066017A3/fr
Priority to IL191931A priority patent/IL191931A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation de Facteur H pour la fabrication d'un médicament destiné au traitement du Syndrome Hémolytique Urémique (SHU), un procédé de purification du Facteur H à partir de plasma frais congelé et le concentré de facteur H obtenu par ce procédé.
PCT/FR2006/002693 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament Ceased WO2007066017A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2006323849A AU2006323849B2 (en) 2005-12-07 2006-12-07 Method for preparing a factor H concentrate and the use thereof in the form of a drug
US12/095,949 US20080318841A1 (en) 2005-12-07 2006-12-07 Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug
JP2008543870A JP2009518368A (ja) 2005-12-07 2006-12-07 因子ｈ濃縮物の調製方法及び薬剤の形でのその使用
EP06841898A EP1962885A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
CA002633102A CA2633102A1 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
BRPI0619728-0A BRPI0619728A2 (pt) 2005-12-07 2006-12-07 método de preparação de um concentrado de fator h e utilização deste concentrado de fator h a tìtulo de medicamento
IL191931A IL191931A0 (en) 2005-12-07 2008-06-03 Method for preparing a factor h concentrate and the use thereof in the form of a drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512404A FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament
FR0512404 2005-12-07

Publications (2)

Publication Number Publication Date
WO2007066017A2 WO2007066017A2 (fr) 2007-06-14
WO2007066017A3 true WO2007066017A3 (fr) 2007-11-08

Family

ID=36928796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/002693 Ceased WO2007066017A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament

Country Status (11)

Country Link
US (1) US20080318841A1 (fr)
EP (1) EP1962885A2 (fr)
JP (2) JP2009518368A (fr)
KR (1) KR20080091441A (fr)
CN (2) CN102988958A (fr)
AU (1) AU2006323849B2 (fr)
BR (1) BRPI0619728A2 (fr)
CA (1) CA2633102A1 (fr)
FR (1) FR2894145B1 (fr)
IL (1) IL191931A0 (fr)
WO (1) WO2007066017A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304524B2 (en) 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US8940877B2 (en) 2010-05-26 2015-01-27 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2627264A1 (fr) 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de nephropathies chroniques et sa production
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
ES2940466T3 (es) * 2008-11-10 2023-05-08 Alexion Pharma Inc Métodos y composiciones para tratar trastornos asociados al complemento
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
FR2952640B1 (fr) 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
FR2952539B1 (fr) 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
WO2012049245A1 (fr) 2010-10-13 2012-04-19 Octapharma Ag Méthode de purification du facteur h du complément
FR2967071A1 (fr) 2010-11-10 2012-05-11 Lab Francais Du Fractionnement Facteur h pour le traitement de maladies auto-immunes du systeme nerveux
FR2981661B1 (fr) * 2011-10-25 2015-06-19 Lfb Biotechnologies Procede de preparation du facteur h humain
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
JP6373963B2 (ja) 2013-03-14 2018-08-15 バクスアルタ インコーポレイテッド 移植のためのｈ因子
AU2014236782B2 (en) 2013-03-14 2019-01-03 Baxalta GmbH Factor H for treatment of rheumatoid arthritis
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
EA034870B1 (ru) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
CN107074939B (zh) * 2014-08-20 2021-09-07 桑昆血液供给基金会 H因子增强抗体及其用途
MX2022000725A (es) 2019-07-17 2022-04-26 Gemini Therapeutics Sub Inc Anticuerpos potenciadores del factor h y usos de estos.
CN113045634B (zh) * 2019-12-28 2023-04-28 四川远大蜀阳药业有限责任公司 一种补体h因子制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883784A (en) * 1985-11-08 1989-11-28 Sankyo Company Limited Human complement factors and their therapeutic use
WO1998023638A2 (fr) * 1996-11-28 1998-06-04 University Of Leicester Inhibiteur du complement
EP1336618A1 (fr) * 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Facteur H du complement de porc et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030983A2 (fr) * 2000-10-13 2002-04-18 Octapharma Ag Fraction de plasma renfermant de la bikunine, son procede de fabrication et son utilisation
CA2627264A1 (fr) * 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de nephropathies chroniques et sa production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883784A (en) * 1985-11-08 1989-11-28 Sankyo Company Limited Human complement factors and their therapeutic use
WO1998023638A2 (fr) * 1996-11-28 1998-06-04 University Of Leicester Inhibiteur du complement
EP1336618A1 (fr) * 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Facteur H du complement de porc et son utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUNDWALL A ET AL: "Isolation of human complement factors C3, C5 and H.", JOURNAL OF IMMUNOLOGICAL METHODS 16 JUL 1985, vol. 81, no. 1, 16 July 1985 (1985-07-16), pages 147 - 160, XP002449173, ISSN: 0022-1759 *
MANUELIAN TAMARA ET AL: "Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.", JOURNAL OF CLINICAL INVESTIGATION, vol. 111, no. 8, April 2003 (2003-04-01), pages 1181 - 1190, XP002397734, ISSN: 0021-9738 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822656B2 (en) 2009-07-23 2014-09-02 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
US9109044B2 (en) 2009-07-23 2015-08-18 Baxalta Incorporated Manufacture of factor H (FH) and FH-derivatives from plasma
US8304524B2 (en) 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
US8940877B2 (en) 2010-05-26 2015-01-27 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US8889838B2 (en) 2010-05-26 2014-11-18 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8921520B2 (en) 2010-05-26 2014-12-30 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US8993734B2 (en) 2010-05-26 2015-03-31 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US9468675B2 (en) 2010-05-26 2016-10-18 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US9708391B2 (en) 2010-05-26 2017-07-18 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US10208106B2 (en) 2010-05-26 2019-02-19 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US10875906B2 (en) 2010-05-26 2020-12-29 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US11891431B2 (en) 2010-05-26 2024-02-06 Takeda Pharm Limited ceutical Company Limited Removal of serine proteases by treatment with finely divided silicon dioxide

Also Published As

Publication number Publication date
US20080318841A1 (en) 2008-12-25
IL191931A0 (en) 2009-02-11
JP2009518368A (ja) 2009-05-07
FR2894145A1 (fr) 2007-06-08
EP1962885A2 (fr) 2008-09-03
CA2633102A1 (fr) 2007-06-14
CN101336111A (zh) 2008-12-31
JP2012211189A (ja) 2012-11-01
AU2006323849A1 (en) 2007-06-14
KR20080091441A (ko) 2008-10-13
WO2007066017A2 (fr) 2007-06-14
BRPI0619728A2 (pt) 2011-10-11
CN102988958A (zh) 2013-03-27
AU2006323849B2 (en) 2012-11-01
FR2894145B1 (fr) 2008-10-17

Similar Documents

Publication Publication Date Title
WO2007066017A3 (fr) Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
EP2982696A3 (fr) Traitement de la leucémie lymphoblastique aiguë
WO2006127898A3 (fr) (s)-n-methylnaltrexone
WO2009010877A3 (fr) Purification de conjugués
WO2007024705A3 (fr) Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
IL177541A0 (en) A method of providing a purified, virus safe antibody preparation
IL185031A0 (en) Method for the preparation of pregabalin and salts thereof
WO2007091266A3 (fr) Alpha-i antitrypsine pour le traitement d'épisodes d'exacerbation de maladies pulmonaires
WO2006072347A3 (fr) Thiophene substitue par un alkinyle
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2007144169A3 (fr) Dérivés d'entacapone
WO2009130604A3 (fr) Formes à l'état solide de sels de déférasirox et leurs procédés de fabrication
EP1820566A4 (fr) Membrane composite semi-perméable et procédé de fabrication de ladite membrane
WO2006124861A3 (fr) Composes de benzofuranne
WO2006018184A3 (fr) Derives de cyclohexane spirocycliques
WO2011147797A3 (fr) Composé hybride, son utilisation et son procédé de préparation
WO2006110831A3 (fr) Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
WO2006072348A3 (fr) Thiophene substitue par un alkinyle
WO2007115929A8 (fr) Thiazolyl-dihydro-quinazolines
EP1806174A4 (fr) Procede de fabrication de membrane composite semi-perméable
EP1825905A4 (fr) Membrane composite semi-perméable et procédé de fabrication de ladite membrane
WO2006034035A3 (fr) Traitement de l'ischemie
WO2008041176A3 (fr) Procédé de préparation de la forme i et de la forme ii du ritonavir
WO2007092607A3 (fr) Traitement d'infections virales hémorragiques au moyen d'un inhibiteur du facteur tissulaire
PL1979053T3 (pl) Produkt do leczenia skóry i błon śluzowych oraz odnośny sposób wytwarzania

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008543870

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2633102

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4949/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006323849

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087016073

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006841898

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006323849

Country of ref document: AU

Date of ref document: 20061207

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006323849

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680052193.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06841898

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12095949

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006841898

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0619728

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080606